APA (7th ed.) Citation

Eriksen, M., Pfeiffer, P., Rohrberg, K. S., Yde, C. W., Petersen, L. N., Poulsen, L. Ø., & Qvortrup, C. (2022). A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: The NEW BEACON study. BMC Cancer, 22(1), 1. https://doi.org/10.1186/s12885-022-10420-x

Chicago Style (17th ed.) Citation

Eriksen, Martina, Per Pfeiffer, Kristoffer Staal Rohrberg, Christina Westmose Yde, Lone Nørgård Petersen, Laurids Østergaard Poulsen, and Camilla Qvortrup. "A Phase II Study of Daily Encorafenib in Combination with Biweekly Cetuximab in Patients with BRAF V600E Mutated Metastatic Colorectal Cancer: The NEW BEACON Study." BMC Cancer 22, no. 1 (2022): 1. https://doi.org/10.1186/s12885-022-10420-x.

MLA (9th ed.) Citation

Eriksen, Martina, et al. "A Phase II Study of Daily Encorafenib in Combination with Biweekly Cetuximab in Patients with BRAF V600E Mutated Metastatic Colorectal Cancer: The NEW BEACON Study." BMC Cancer, vol. 22, no. 1, 2022, p. 1, https://doi.org/10.1186/s12885-022-10420-x.